Published in J Clin Invest on March 01, 1991
A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest (1995) 7.68
Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest (1992) 4.49
Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy. Clin Microbiol Rev (2004) 1.95
Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J Exp Med (1994) 1.43
Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin Microbiol Rev (2002) 1.12
The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-β1 production and FcRL4 expression. Nat Immunol (2013) 1.04
Retinoic acid mimics transforming growth factor beta in the regulation of human immunodeficiency virus expression in monocytic cells. Proc Natl Acad Sci U S A (1992) 0.93
The expression of HIV-1 Vpu in monocytes causes increased secretion of TGF-β that activates profibrogenic genes in hepatic stellate cells. PLoS One (2014) 0.87
Morphine-induced macrophage apoptosis: the role of transforming growth factor-beta. Immunology (2000) 0.86
Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology (1997) 0.85
Human immunodeficiency virus tat gene transfer to the murine central nervous system using a replication-defective herpes simplex virus vector stimulates transforming growth factor beta 1 gene expression. Proc Natl Acad Sci U S A (1996) 0.83
Effect of Probiotic Supplement on Cytokine Levels in HIV-Infected Individuals: A Preliminary Study. Nutrients (2015) 0.82
A reasonable Approach for the Treatment of HIV Infection in the Early Phase with Ozonetherapy (Autohaemotherapy). How 'Inflammatory' Cytokines may have A therapeutic Role. Mediators Inflamm (1994) 0.82
Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia. Haemophilia (2010) 0.81
Frequencies of HIV-reactive B cells in seropositive and seronegative individuals. Clin Exp Immunol (1992) 0.78
The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science (1988) 11.05
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science (1984) 5.20
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol (1988) 4.34
The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med (1988) 4.31
IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1989) 4.03
Infection with HIV is associated with elevated IL-6 levels and production. J Immunol (1990) 3.89
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med (1989) 3.28
Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med (1987) 3.03
Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med (1984) 2.93
B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med (1988) 2.88
Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol (1988) 2.70
Separate signals for human B cell proliferation and differentiation in response to Staphylococcus aureus: evidence for a two-signal model of B cell activation. J Immunol (1982) 2.48
Induction of IL-6 (B cell stimulatory factor-2/IFN-beta 2) production by HIV. J Immunol (1989) 2.27
Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin. J Biol Chem (1987) 2.15
Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med (1986) 2.03
Mechanism for transforming growth factor beta and IL-2 enhancement of IgA expression in lipopolysaccharide-stimulated B cell cultures. J Immunol (1990) 1.71
Defective B-lymphocyte function in homosexual men in relation to the acquired immunodeficiency syndrome. Ann Intern Med (1984) 1.63
Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. Clin Exp Immunol (1987) 1.56
Human transforming growth factor type beta 2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization. Biochemistry (1987) 1.55
Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci U S A (1990) 1.55
Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. J Clin Invest (1990) 1.49
Beta transforming growth factors are potential regulators of B lymphopoiesis. J Exp Med (1987) 1.39
Transforming growth factor-beta 1 is a costimulator for IgA production. J Immunol (1990) 1.33
Further studies of the role of transforming growth factor-beta in human B cell function. J Immunol (1989) 1.13
Antigen-specific and polyclonal B-cell responses in patients with acquired immunodeficiency disease syndrome. Clin Immunol Immunopathol (1986) 1.11
Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes. Exp Cell Res (1987) 1.02
Epstein-Barr virus mediates a switch in responsiveness to transforming growth factor, type beta, in cells of the B cell lineage. Eur J Immunol (1987) 0.91
Hypergammaglobulinemia associated with human immunodeficiency virus infection. Monogr Allergy (1988) 0.88
The relationship of serum IgA concentration to human immunodeficiency virus (HIV) infection: a cross-sectional study of HIV-seropositive individuals detected by screening in the United States Air Force. J Allergy Clin Immunol (1988) 0.87
Abnormal B-cell response to T-cell-independent polyclonal B-cell activators in homosexuals presenting persistent generalized lymph node enlargement and HTLV-III antibodies. Diagn Immunol (1986) 0.85
Predominance of the IgG1 subclass in the hypergammaglobulinemia observed in pre-AIDS and AIDS. Cancer Detect Prev (1988) 0.82
Increased IgA as a predictor of development of AIDS in HIV-infected subjects. Clin Chem (1988) 0.76
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum (1994) 14.16
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (1994) 6.06
The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc (1995) 5.38
Cefoxitin as a single-dose treatment for urethritis caused by penicillinase-producing Neisseria gonorrhoeae. N Engl J Med (1979) 5.15
Penicillinase-producing Neisseria gonorrhoeae in Great Britain, 1977-81: alarming increase in incidence and recent development of endemic transmission. Br Med J (Clin Res Ed) (1982) 4.95
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med (1982) 4.28
Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 4.12
Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology (2009) 4.07
Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 3.82
Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol (1997) 3.38
Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med (1990) 3.37
Evidence for a phosphorus-depletion syndrome in man. N Engl J Med (1968) 3.34
Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med (1989) 3.33
Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology (1992) 3.15
An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum (2000) 3.06
Cytokines in symptomatic asthma airways. J Allergy Clin Immunol (1992) 3.01
Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol (1989) 3.01
Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science (1988) 2.96
Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A (1977) 2.90
B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med (1988) 2.88
Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest (1989) 2.83
Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest (1991) 2.82
THE INFLUENCE OF IODINE ON THE EXCRETION OF CREATINE IN EXOPHTHALMIC GOITER. J Clin Invest (1929) 2.73
Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol (2001) 2.69
Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A (1994) 2.58
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med (1992) 2.57
Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation. Nature (1986) 2.49
Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med (1987) 2.46
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med (1990) 2.45
The x gene is essential for HTLV replication. Science (1985) 2.44
Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem (1998) 2.43
Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. J Biol Chem (1988) 2.41
Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center. Psychosom Med (1994) 2.39
Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. Arch Gen Psychiatry (1988) 2.36
In vitro effects of Epstein-Barr virus on peripheral blood mononuclear cells from patients with rheumatoid arthritis and normal subjects. J Exp Med (1978) 2.34
Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J Natl Cancer Inst (2000) 2.33
Radioimmunoassay of IgG and IgM rheumatoid factors reacting with human IgG. J Immunol (1977) 2.21
Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. Arthritis Rheum (1998) 2.19
Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med (1996) 2.18
Chondrocyte apoptosis induced by nitric oxide. Am J Pathol (1995) 2.16
Influence of colony type on susceptibility of gonococci to killing by human serum. J Immunol (1976) 2.14
Anticytoplasmic antibodies in Wegener's granulomatosis. Lancet (1986) 2.12
Binding of host-cell factors to DNA sequences in the long terminal repeat of human T-cell leukemia virus type I: implications for viral gene expression. Proc Natl Acad Sci U S A (1988) 2.12
Nucleotide sequence of the 3' region of an infectious human T-cell leukemia virus type II genome. Proc Natl Acad Sci U S A (1984) 2.10
Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med (1996) 2.10
Autoantibodies against cytoplasmic structures of neutrophil granulocytes in Wegener's granulomatosis. Clin Exp Immunol (1987) 2.09
Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization. J Infect Dis (1990) 2.08
A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. Oncogene (2000) 2.07
A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med (1991) 2.06
Variable region sequences of murine IgM anti-IgG monoclonal autoantibodies (rheumatoid factors). A structural explanation for the high frequency of IgM anti-IgG B cells. J Exp Med (1986) 2.04
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis (2007) 2.01
Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A (1996) 2.01
Improved differentiation between Churg-Strauss syndrome and Wegener's granulomatosis by an artificial neural network. Arthritis Rheum (2001) 2.00
Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol (1997) 2.00
Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis (1994) 1.99
A factor analysis of the Klein sexual orientation grid in two disparate samples. Arch Sex Behav (1993) 1.98
Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest (1985) 1.98
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) (2002) 1.98
Characterization of the human granulocyte-macrophage colony-stimulating factor promoter region by genetic analysis: correlation with DNase I footprinting. Mol Cell Biol (1988) 1.97
Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science (1987) 1.97
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) (2007) 1.95
Cell death in cartilage. Osteoarthritis Cartilage (2004) 1.94
A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. J Infect Dis (1993) 1.93
A conserved human germline V kappa gene directly encodes rheumatoid factor light chains. J Exp Med (1986) 1.92
Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol (1999) 1.89
Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology (2000) 1.88
Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment. Br Med J (Clin Res Ed) (1983) 1.85
Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum (2001) 1.85
IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J Immunol (1990) 1.82
Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci U S A (2000) 1.81
Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci U S A (1978) 1.79
Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol (1994) 1.76
Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy. J Exp Med (1988) 1.73
Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A (1979) 1.72
Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol (1992) 1.72
Rheumatoid factor and immune networks. Annu Rev Immunol (1987) 1.70
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol (2005) 1.68
Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. HIV Neurobehavioral Research Center Group. Arch Neurol (1998) 1.66
Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (1989) 1.66
A common idiotope on human rheumatoid factors identified by a hybridoma antibody. Mol Immunol (1983) 1.65
Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J Exp Med (1987) 1.65
2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol (1992) 1.65
IgG rheumatoid factor in subacute bacterial endocarditis: relationship to IgM rheumatoid factor and circulating immune complexes. Clin Exp Immunol (1978) 1.62
Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis (1994) 1.61
Cyclosporin for acute dermatomyositis. Lancet (1984) 1.61
Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis (1998) 1.61
Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol (1994) 1.61
Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med (1989) 1.61
DNA strand breaks, NAD metabolism, and programmed cell death. Exp Cell Res (1986) 1.60
A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology (1990) 1.60
Castleman's disease in POEMS syndrome with elevated interleukin-6. Cancer (1992) 1.59